Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

Posttransplant lymphoproliferative disorders (PTLDs) represent a life-threatening complication of standard immunosuppressive therapy. The impact of novel, rapamycin-related immunosuppressive drugs on the pathogenesis of PTLDs remains undefined. We tested the effect of everolimus (RAD, Novartis Pharm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplantation 2003-05, Vol.75 (10), p.1710-1717
Hauptverfasser:	Majewski, Miroslaw, Korecka, Magdalena, Joergensen, Joanne, Fields, Leona, Kossev, Plamen, Schuler, Walter, Shaw, Leslie, Wasik, Mariusz A
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cell Cycle - drug effects Cell Division - drug effects Cell Survival - drug effects Cell Transplantation Dose-Response Relationship, Drug Everolimus Graft Rejection - prevention & control graft survival Graft Survival - drug effects Heart Transplantation - adverse effects Humans Immunosuppressive Agents - administration & dosage Liver Transplantation - adverse effects lymphoproliferative diseases Lymphoproliferative Disorders - etiology Lymphoproliferative Disorders - pathology Mice Mice, Inbred Strains Mice, SCID Protein Kinase Inhibitors Protein Kinases Sirolimus - administration & dosage Sirolimus - analogs & derivatives TOR Serine-Threonine Kinases Transplantation, Heterologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!